General Information of Drug (ID: DM2U4XQ)

Drug Name
ALCURONIUM Drug Info
Synonyms Alcuronium
Indication
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [1]
Cross-matching ID
PubChem CID
21158560
ChEBI ID
CHEBI:55313
CAS Number
CAS 23214-96-2
TTD Drug ID
DM2U4XQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Investigative Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ziprasidone DMM58JY Bipolar disorder 6A60 Approved [4]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [5]
CYTISINE DMUF0BJ Tobacco dependence 6C4A.2 Phase 3 [6]
EVP-6124 DMLQO7F Alzheimer disease 8A20 Phase 3 [7]
GTS-21 DMEN5KA Parkinson disease 8A00.0 Phase 2 [8]
JNJ-39393406 DMUOEKM Depression 6A70-6A7Z Phase 2 [9]
ABT-126 DM2OS51 Alzheimer disease 8A20 Phase 2 [10]
TC-6987 DMNFP21 Asthma CA23 Phase 2 [11]
AQW-051 DMD2RFO Alzheimer disease 8A20 Phase 2 [12]
MEM-3454 DMPNDYU Schizophrenia 6A20 Phase 2 [4]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [13]
Acetylcholine DMDF79Z Cataract 9B10 Approved [14]
Atropine DMEN6X7 Organophosphate poisoning NE6Z Approved [3]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [15]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [16]
Methylscopolamine DM5VWOB Peptic ulcer DA61 Approved [17]
Carbachol DMX9K8F Glaucoma/ocular hypertension 9C61 Approved [17]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [18]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [19]
brucine DM50RUD Discovery agent N.A. Investigative [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neuronal acetylcholine receptor alpha-7 (CHRNA7) TTLA931 ACHA7_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Muscarinic acetylcholine receptor M4 (CHRM4) OTF0F0FF ACM4_HUMAN Protein Interaction/Cellular Processes [3]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 341).
2 Pharmacological characteristics and binding modes of caracurine V analogues and related compounds at the neuronal alpha7 nicotinic acetylcholine re... J Med Chem. 2007 Sep 20;50(19):4616-29.
3 Interaction studies of multiple binding sites on m4 muscarinic acetylcholine receptors. Mol Pharmacol. 2006 Aug;70(2):736-46. doi: 10.1124/mol.106.024711. Epub 2006 May 18.
4 The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22.
5 Clinical pipeline report, company report or official report of Roche (2009).
6 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett. 2005 Nov 15;15(22):4889-97.
7 Normalizing effects of EVP-6124, an alpha-7 nicotinic partial agonist, on event-related potentials and cognition: a proof of concept, randomized trial in patients with schizophrenia. J Psychiatr Pract. 2014 Jan;20(1):12-24.
8 The brain alpha7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease: studies with DMXBA (GTS-21). Behav Brain Res. 2000 Aug;113(1-2):169-81.
9 Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study. Neuropharmacology. 2013 Jan;64:197-204.
10 A phase 2 randomized, controlled trial of the alpha7 agonist ABT-126 in mild-to-moderate Alzheimer's dementia. Alzheimer's & Dementia: Translational Research & Clinical Interventions Volume 1, Issue 1, June 2015, Pages 81-90.
11 ClinicalTrials.gov (NCT01293669) Glycemic Control, Safety and Tolerability of TC-6987 Monotherapy in Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
12 AQW051, a novel and selective nicotinic acetylcholine receptor alpha7 partial agonist, reduces l-Dopa-induced dyskinesias and extends the duration of l-Dopa effects in parkinsonian monkeys. Parkinsonism Relat Disord. 2014 Nov;20(11):1119-23.
13 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
14 Allosteric effects of four stereoisomers of a fused indole ring system with 3H-N-methylscopolamine and acetylcholine at M1-M4 muscarinic receptors. Life Sci. 1999;64(6-7):519-26. doi: 10.1016/s0024-3205(98)00596-7.
15 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
16 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
17 Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol. 1997 Jul;52(1):172-9.
18 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
19 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.